Alongside the release of abstracts related to the American Society of Hematology meeting next month in San Diego, and as part of the firm’s third-quarter update, Beam Therapeutics Inc. disclosed that ...
Karolinska Development AB has announced that its portfolio company Dilaforette AB has enrolled the first patient in a clinical Phase II study with sevuparin in patients with sickle-cell disease (SCD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results